Novartis Rhapsido FDA Approval: Remibrutinib Becomes First Treatment for Symptomatic Dermographism
The Novartis Rhapsido FDA approval makes remibrutinib the first approved treatment for adults with symptomatic dermographism not controlled by H1 antihistamines. It builds on Rhapsido’s existing chronic spontaneous urticaria indication.
